{
  "documentMetadata": {
    "title": "Erysipelas, Recurrent, Lymphedema",
    "lastUpdated": "2020-08-19",
    "sourceFile": "Erysipelas, Recurrent, Lymphedema.pdf"
  },
  "content": [
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Clinical Setting"
        },
        {
          "type": "list",
          "items": [
            "Patients with chronic lymphedema suffer recurrent episodes of erysipelas due to Streptococcus sp., group A, B, C, G.",
            "Lymphedema can be congenital, e.g., Milroy's Disease, or acquired, e.g., post-lymph node dissection for cancer.",
            "It is believed that each episode of erysipelas damages lymphatics, thereby promotes lymphedema and hence increases the risk of recurrent episodes of erysipelas (cellulitis).",
            "Benefit of prophylaxis documented in double-blind randomized controlled trial, P=0.02. Prophylaxis failures associated with high BMI, preexisting edema, and three or more previous episodes of \"cellulitis\". It is unclear how long to continue the prophylaxis. References: N Engl J Med 368:1695, 2013; Clin Infect Dis 59:147, 2014."
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Etiologies"
        },
        {
          "type": "list",
          "items": [
            "Streptococcus sp. (Group A, B, C, G)"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Primary Regimens"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "components": [
              {
                "drug": "Penicillin VK",
                "dose": "250 mg",
                "route": "po",
                "frequency": "bid"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Alternative Regimens"
        },
        {
          "type": "paragraph",
          "text": "All for prophylaxis:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "components": [
              {
                "drug": "Benzathine Penicillin G",
                "dose": "1.2 million units",
                "route": "IM",
                "frequency": "q4 weeks"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "components": [
              {
                "drug": "Erythromycin",
                "dose": "500 mg",
                "route": "po",
                "frequency": "q24h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "components": [
              {
                "drug": "Azithromycin",
                "dose": "250 mg",
                "route": "po",
                "frequency": "q24h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "components": [
              {
                "drug": "Clarithromycin",
                "dose": "500 mg",
                "route": "po",
                "frequency": "q24h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "prophylaxis",
            "condition": "If penicillin intolerant",
            "components": [
              {
                "drug": "Cephalexin",
                "dose": "250 mg",
                "route": "po",
                "frequency": "bid"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Comments"
        },
        {
          "type": "list",
          "items": [
            "In randomized trial comparing compression therapy with no compression, trial stopped for efficacy of compression therapy, p = 0.002 (New Engl J Med 2020;383: 630).",
            "Prophylaxis is only indicated for patients suffering frequent episodes of erysipelas; defined as 2 episodes of documented cellulitis over the last 3 years.",
            "Note: stasis dermatitis can mimic cellulitis and is not due to a bacterial infection."
          ]
        }
      ]
    }
  ]
}